DDInter1141 DDInter119
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Megestrol acetate {u} (Compound) binds {v} (Gene) PGR
Megestrol acetate {u} (Compound) palliates {v} (Disease) breast cancer
Megestrol acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Megestrol acetate (Compound) resembles Dydrogesterone (Compound)
Megestrol acetate (Compound) resembles Methyltestosterone (Compound)
Megestrol acetate (Compound) binds PGR (Gene)
Megestrol acetate (Compound) palliates breast cancer (Disease)
Megestrol acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)